Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hemangioblastoma × Propranolol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hemangioma 9 Hemangioma, Capillary 6 Melanoma 5 Breast Neoplasms 4 Sarcoma 3 Hemangiosarcoma 3 Fallopian Tube Neoplasms 3 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Multiple Myeloma 2 Hemangioma, Cavernous, Central Nervous System 2 Carcinoma, Ovarian Epithelial 2 von Hippel-Lindau Disease 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Ulcer 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Spinal Cord Neoplasms 1 Smoldering Multiple Myeloma 1 Skin Neoplasms 1 Sarcoma, Kaposi 1 Recurrent respiratory papillomatosis 1 Recurrence 1 Papilloma 1 Ovarian Neoplasms 1 Neuroblastoma 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1

Interventions

belzutifan 1 Sunitinib 1 Propranolol 1 Nivolumab 1 Bevacizumab 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05424016 2023-12-13

PRO-HEB

Assistance Publique - Hôpitaux de Paris

Phase NA Recruiting

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡